Beta Testing New Roles of Cyclic Guanosine Monophosphate in Cardiac Myocyte Contractility
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Blanton R
. cGMP Signaling and Modulation in Heart Failure. J Cardiovasc Pharmacol. 2019; 75(5):385-398.
PMC: 7044023.
DOI: 10.1097/FJC.0000000000000749.
View
2.
Lee D, Vahebi S, Tocchetti C, Barouch L, Solaro R, Takimoto E
. PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic Res Cardiol. 2010; 105(3):337-47.
PMC: 2878662.
DOI: 10.1007/s00395-010-0084-5.
View
3.
Blanton R, Takimoto E, Lane A, Aronovitz M, Piotrowski R, Karas R
. Protein kinase g iα inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J Am Heart Assoc. 2013; 1(5):e003731.
PMC: 3541610.
DOI: 10.1161/JAHA.112.003731.
View
4.
Lee D, Zhu G, Sasaki T, Cho G, Hamdani N, Holewinski R
. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature. 2015; 519(7544):472-6.
PMC: 4376609.
DOI: 10.1038/nature14332.
View
5.
Takimoto E, Champion H, Li M, Belardi D, Ren S, Rodriguez E
. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005; 11(2):214-22.
DOI: 10.1038/nm1175.
View